<DOC>
	<DOCNO>NCT01756404</DOCNO>
	<brief_summary>The purpose study ass pharmacokinetics ( ie , body affect drug ) pharmacodynamics ( ie , drug affect body ) increase dos canagliflozin ( JNJ-28431754 ) healthy obese volunteer .</brief_summary>
	<brief_title>Study Assess Pharmacokinetics , Pharmacodynamics , Safety Canagliflozin ( JNJ-28431754 ) Otherwise Healthy Obese Volunteers</brief_title>
	<detailed_description>This study single-center , randomize ( treatment assign chance ) , double-blind ( neither investigator volunteer know identity assign treatment ) , placebo-controlled ( one study medication inactive ) , ascend multiple dose study ( increase dos study medication ) ass pharmacokinetics pharmacodynamics canagliflozin ( drug currently investigate treatment type 2 diabetes mellitus ) otherwise healthy obese volunteer . The study consist 3 phase : screening phase , double-blind treatment phase , end study ( follow-up ) phase . Volunteers assign 5 cohort ( group ) make 16 otherwise healthy obese men woman . Within group , 12 volunteer give canagliflozin twice daily 4 volunteer give placebo ( inactive medication ) twice daily 14 day . The dose canagliflozin different 5 group second group begin treatment least 21 day first group start treatment . This 21-day gap apply subsequent group . Each volunteer participate study approximately 58 day .</detailed_description>
	<mesh_term>Canagliflozin</mesh_term>
	<criteria>Volunteers must body mass index ( BMI = weight kg/height m2 ) 30.0 39.9 kg/m2 Volunteers must nondiabetic confirm fast plasma glucose &lt; 126 mg/dL Volunteers must nonsmoker nontobacco user ( smoke cigarette use tobaccocontaining product 3 month prior screen ) History currently active illness consider clinically significant Investigator illness Investigator considers exclude patient study could interfere interpretation study result History take antiobesity medication ( prescription nonprescription ) within 3 month screen visit , anticipate need take drug course study History gastric banding , gastric bypass gastricreduction surgery History eating disorder recent significant change body weight due diet nutritional treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Healthy</keyword>
	<keyword>Canagliflozin ( JNJ-28431754 )</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Pharmacodynamics</keyword>
	<keyword>Obesity</keyword>
</DOC>